Table 1.

Summary of the VHX (columns one to three) and the BPD (columns four and five) trial features.

	AS	CQ	PMQ + CQ	PMQ + CQ	PMQ + DP
Number of patients, $n$	224	222	198	329	326
Male patients (%)	71	65	64	66	63
Median patient age [years] (range)	19 (1.5–62)	18 (1.5–62)	18 (2–63)	20 (1.5–61)	20 (1.3–63)
Median days follow-up (range)	314 (1–393)	364 (11–412)	364 (0–383)	364 (7–415)	364 (7–685)
Geometric mean parasites per μL at enrolment (range)	4113 (144–47,665)	3920 (168–44,211)	3524 (136–62,298)	4134 (32–59,032)	3726 (48–381,824)
Number of patients whose infections recurred, $n_{\mathrm{r}}$ (% of $n$)	177 (39)	165 (36)	35 (8)	47 (10)	34 (7)
$n_{\mathrm{r}}$ with one or more paired recurrence genotyped and analysed (% of $n_{\mathrm{r}}$)	11 (6)	88 (53)	32 (91)	46 (98)	31 (91)
Number of recurrences, $\mathrm{r}$	722	587	40	53	39
Number of paired recurrences genotyped and analysed (% of $\mathrm{r}$)	11 (2)	355 (60)	34 (85)	52 (98)	35 (90)

Treatment allocation was randomised in both trials. Genetic data are reported in terms of the number of paired recurrences genotyped and analysed, since episode pairs are required for recurrence state inference and some paired recurrences were not analysed due to computational complexity. Five patients had unpaired thus unanalyzable genetic data. Data from six paired recurrences were omitted due to computational complexity

AS artesunate, CQ chloroquine, PMQ primaquine, DP dihydroartemisinin-piperaquine